GLOW vs KLOW vs Wolverine vs CJC-1295 + Ipamorelin: what these names mean, what is actually in the commonly encountered formulations, what the individual research shows, and how multi-component concentration mathematics works.
Direct answer: Peptide “stack” names are not automatically standardized scientific formulations. GLOW, KLOW, and Wolverine are primarily market or research-community labels, while CJC-1295 + ipamorelin describes two pharmacologically distinct compounds. The components may have individual research evidence, but that does not establish the safety or efficacy of the complete combination.
At a glance
Peptide Stack Snapshot
Stack
Commonly encountered components
Standardized?
Complete-combination evidence
Individual-component evidence
Classification
GLOW
GHK-Cu + BPC-157 + TB-500
No universal standard
No established controlled human combination trial identified
Different evidence bases; largely preclinical for BPC-157/TB-500, with some human/topical GHK-Cu research
Market / research-community name
KLOW
GHK-Cu + BPC-157 + TB-500 + KPV
No universal standard
No controlled human combination evidence identified
Independent component literature; largely preclinical for the relevant repair/inflammatory claims
Market / research-community name
Wolverine
BPC-157 + TB-500
No fixed formula
Do not treat the nickname as evidence of synergy
Independent preclinical evidence exists for the individual compounds / related thymosin beta-4 literature
Community nickname
CJC-1295 + Ipamorelin
CJC-1295 + ipamorelin
Not a single standardized product
No basis to call the combination clinically validated
CJC-1295 has human pharmacodynamic research; ipamorelin has human research but significant safety/regulatory uncertainty
Two-compound research/compounding pairing
Visual reference
How the Stack Names Relate
Figure 1. Conceptual comparison of commonly encountered stack labels. This diagram describes terminology and composition patterns, not treatment protocols.
Definitions
What Are GLOW, KLOW, Wolverine and CJC-1295 + Ipamorelin?
Market / research name
GLOW
GLOW is commonly used as a shorthand for a three-component blend containing GHK-Cu, BPC-157 and TB-500. It is not a universally defined pharmaceutical formulation.
GHK-Cu Copper-associated tripeptide.
BPC-157 Synthetic pentadecapeptide investigated primarily in preclinical research.
TB-500 Market terminology associated with thymosin-beta-4-related peptide material.
Formulation warning: GLOW labels should not be assumed to represent one universal mass ratio. Published and commercial examples include different component amounts.
Market / research name
KLOW
KLOW is commonly used for a four-component blend consisting of GHK-Cu, BPC-157, TB-500 and KPV. The frequently encountered 80 mg example is 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 + 10 mg KPV.
GHK-Cu 50 mg in the commonly cited 80 mg example.
BPC-157 10 mg in the commonly cited example.
TB-500 10 mg in the commonly cited example.
KPV 10 mg in the commonly cited example.
Formulation warning: Other mass splits are encountered. KLOW should therefore be identified by its component list and measured mass, not by the name alone.
Community nickname
Wolverine
“Wolverine” is a community nickname commonly used for the pairing of BPC-157 and TB-500. The name is an analogy to fictional regenerative healing and is not a scientific formulation name.
BPC-157 — individually studied mainly in preclinical models.
There is no universally defined “Wolverine vial.” Any concentration calculation must therefore use the actual mass of BPC-157 and TB-500 in the specific vial.
Two-compound pairing
CJC-1295 + Ipamorelin
CJC-1295 and ipamorelin act through different growth-hormone-axis mechanisms. They should not be grouped with GLOW/KLOW simply because both are discussed online as “peptide stacks.”
CJC-1295 A growth-hormone-releasing hormone analogue. DAC and non-DAC terminology is important.
Ipamorelin A growth-hormone secretagogue.
DAC distinction: Published human CJC-1295 data prominently concern the long-acting DAC form. That evidence should not automatically be transferred to an unspecified “CJC-1295 no-DAC” product.
Formulation comparison
Commonly Encountered Formulations
The table below intentionally separates documented examples from universal standards. A formulation appearing in multiple commercial or research listings does not make it a clinically standardized pharmaceutical composition.
Stack
Example formulation
Total peptide mass
Ratio
Standardized?
Interpretation
GLOW
GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg
70 mg
5 : 1 : 1
No
Commonly encountered formulation, not a universal standard.
GLOW variant
GHK-Cu 35 mg + BPC-157 5 mg + TB-500 10 mg
50 mg
7 : 1 : 2
No
Illustrates why the label alone cannot establish concentration.
Nickname for a pairing; no universal vial composition.
CJC-1295 + Ipamorelin
Variable CJC-1295 + variable ipamorelin
Variable
Variable
No
Specific salt/form, DAC status and labeled mass must be verified.
Important: These are formulation examples for identification and concentration mathematics. They are not recommended doses, administration instructions, or treatment protocols.
Evidence by component
What Does the Research Show for the Individual Components?
Component
GHK-Cu
GHK-Cu has a longer research history than several of the other compounds in these stacks. Research includes cellular, tissue, animal and some human/topical studies involving skin remodeling, wound biology and extracellular-matrix-related endpoints.
Human evidence does not establish that injectable GHK-Cu in a multi-peptide stack produces the outcomes promoted by online marketing.
Component
BPC-157
BPC-157 has substantial preclinical literature involving tissue repair, vascular signaling and gastrointestinal or musculoskeletal models.
The major limitation is translation: preclinical findings do not establish human efficacy, appropriate clinical dosing, long-term safety or the performance of BPC-157 inside a multi-component vial.
Component
TB-500 / Thymosin-beta-4 terminology
Thymosin beta-4 has been studied in wound-healing and cell-migration research, including human studies of topical thymosin beta-4.
However, human research involving full-length thymosin beta-4 should not automatically be represented as clinical evidence for every material marketed as “TB-500.” Chemical identity matters.
Component
KPV
KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone. Research has examined anti-inflammatory mechanisms, epithelial biology and inflammatory models.
These mechanistic and preclinical findings do not establish clinical efficacy of KPV as part of KLOW.
Component
CJC-1295
Randomized human studies of CJC-1295 have demonstrated sustained increases in GH and IGF-1 following administration of the studied long-acting compound.
The important limitation is formulation specificity. Evidence for CJC-1295 DAC should not be automatically applied to an unspecified CJC-1295 product or to CJC-1295 without DAC.
Component
Ipamorelin
Ipamorelin has been investigated as a growth-hormone secretagogue. However, the regulatory and safety evidence is not sufficient to treat internet formulations as established clinical protocols.
FDA materials specifically identify concerns involving characterization, peptide impurities and limited route-specific safety information.
Combination evidence
Has the Complete Stack Been Clinically Studied?
Do not extrapolate
GLOW
Evidence for GHK-Cu, BPC-157 and TB-500 individually does not establish that the three-compound GLOW combination is clinically effective or safe. No controlled human trial should be implied merely because individual component studies exist.
Do not extrapolate
KLOW
KLOW adds KPV to the GLOW-style three-component grouping. The existence of mechanistic research on KPV does not establish the four-component KLOW blend as a clinically validated formulation.
Nickname ≠ trial
Wolverine
The Wolverine label describes a community pairing of BPC-157 and TB-500. Individual research should remain separate from claims about synergy between the two.
Combination not validated
CJC-1295 + Ipamorelin
Human research exists for CJC-1295 and research exists for ipamorelin, but this does not mean a particular CJC-1295 + ipamorelin compounded mixture is a clinically validated combination.
Evidence rule: Component evidence → tells us what has been studied about the component. Combination evidence → requires studies of the actual combination. Market practice → tells us what people sell or discuss. These three categories must never be presented as interchangeable.
Concentration mathematics
Stack BAC Water & Concentration Reference
Core rule: every component in a multi-component vial shares the same final liquid volume, but each component retains its own mass. Therefore, each concentration must be calculated independently.
The formula
concentration (mg/mL) = component mass (mg) ÷ final liquid volume (mL)
Never add all peptide masses together and then label the resulting number as the concentration of each component.
For example, a hypothetical research vial containing 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500 would contain 70 mg total peptide material. If the final liquid volume were 5 mL, the individual concentrations would be:
GHK-Cu = 50 ÷ 5 = 10 mg/mL
BPC-157 = 10 ÷ 5 = 2 mg/mL
TB-500 = 10 ÷ 5 = 2 mg/mL
These examples demonstrate concentration mathematics only. They do not recommend a reconstitution volume or a human administration protocol.
Example concentration matrix
GLOW Example: 50 / 10 / 10 mg
The following matrix uses a commonly encountered GLOW-style example: GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg. The table is mathematical, not a recommended volume.
Component
Mass
1 mL
2 mL
3 mL
5 mL
GHK-Cu
50 mg
50 mg/mL
25 mg/mL
16.67 mg/mL
10 mg/mL
BPC-157
10 mg
10 mg/mL
5 mg/mL
3.33 mg/mL
2 mg/mL
TB-500
10 mg
10 mg/mL
5 mg/mL
3.33 mg/mL
2 mg/mL
Example concentration matrix
KLOW Example: 50 / 10 / 10 / 10 mg
Using the commonly cited 80 mg example, every component is divided by the same final liquid volume.
Component
Mass
1 mL
2 mL
3 mL
5 mL
GHK-Cu
50 mg
50 mg/mL
25 mg/mL
16.67 mg/mL
10 mg/mL
BPC-157
10 mg
10 mg/mL
5 mg/mL
3.33 mg/mL
2 mg/mL
TB-500
10 mg
10 mg/mL
5 mg/mL
3.33 mg/mL
2 mg/mL
KPV
10 mg
10 mg/mL
5 mg/mL
3.33 mg/mL
2 mg/mL
Variable formulation
Wolverine Concentration Logic
Wolverine is different because the name does not establish the mass of either component. Therefore, there is no single universal Wolverine concentration table.
If a particular research vial contains:
BPC-157 = B mg
TB-500 = T mg
Final liquid volume = V mL
BPC-157 concentration = B ÷ V mg/mL
TB-500 concentration = T ÷ V mg/mL
The correct calculation must come from the actual vial label or analytical documentation. The nickname “Wolverine” is not sufficient.
Visual mathematics
Why More Liquid Lowers Every Component's Concentration
Figure 2. A fixed component mass produces different mg/mL values as final liquid volume changes.
Educational calculator
Multi-Component Concentration Calculator
Enter component masses
Calculated concentrations
Component
Mass
Concentration
Every row uses: component mass ÷ final liquid volume = mg/mL
This calculator performs concentration arithmetic only. It does not calculate a human dose, injection volume, frequency, administration route, or treatment plan.
BacScience Tool
Need to Calculate Another Vial or BAC-Water Volume?
Use the universal BAC Water Calculator for single-compound concentration mathematics. For multi-component vials, enter and calculate every component separately.
Why Are These Compounds Combined in Market or Research Practice?
GHK-Cu
Often associated with extracellular-matrix, skin and tissue-remodeling research.
BPC-157
Commonly associated with preclinical tissue-repair and vascular signaling research.
TB-500
Commonly associated with thymosin-beta-4-related cell migration and wound-healing biology.
KPV
Included in KLOW because of its experimental anti-inflammatory literature.
These are research rationales for why compounds may be grouped together. They are not proof that the compounds work synergistically in humans.
Important terminology
CJC-1295: DAC vs Non-DAC
DAC
CJC-1295 with Drug Affinity Complex
The long-acting DAC form has been evaluated in randomized human studies. One study reported dose-dependent increases in GH and IGF-1 following administration to healthy adults.
Those results describe the compound studied in that trial and should not automatically be generalized to every commercial CJC-1295 formulation.
Verify identity
CJC-1295 without DAC
“No DAC” is commonly used online to describe shorter-acting CJC-related material. The phrase should not be treated as a synonym for the long-acting compound studied in the classic CJC-1295 human trials.
Product identity, chemical form, salt, analytical documentation and labeling must be considered before transferring evidence from one formulation to another.
Evidence status
Research Status by Stack
Not established
GLOW
No basis to present the three-component blend as a clinically validated combination.
Not established
KLOW
Individual component research exists, but the four-component formulation is not established by controlled clinical evidence.
Nickname
Wolverine
A community label for a BPC-157 + TB-500 pairing, not a standardized clinical formulation.
Individual evidence
CJC + Ipamorelin
Individual human research exists, but evidence for a specific combined formulation should be assessed separately.
Regulatory context
Regulatory & Safety Considerations
Research-use distinction: A research compound or commercially marketed peptide blend should not be represented as an FDA-approved medicine merely because individual ingredients have appeared in scientific studies.
FDA materials identify safety and characterization concerns for multiple compounds discussed on this page. These include concerns relating to immunogenicity, aggregation, peptide-related impurities and limited human safety information for certain proposed routes.
In particular, FDA materials identify limited safety information for BPC-157, CJC-1295, injectable GHK-Cu, KPV and TB-500, while ipamorelin acetate has also been discussed in the context of potential immunogenicity and peptide-related impurities.
Important for research readers: Analytical identity, purity, net content, sterility/endotoxin testing and lot traceability are separate questions. A high purity percentage does not by itself establish clinical safety or therapeutic efficacy.
Interpretation limits
Research Limitations
1. Formulation variability
The same marketing name may appear with different component masses. Concentration therefore cannot be inferred from the stack name.
2. Component ≠ combination
Studies of individual compounds cannot establish that the full stack is synergistic, effective or safe.
3. Chemical identity matters
“TB-500,” thymosin beta-4 and related fragments should not be treated as interchangeable without verifying molecular identity.
4. DAC status matters
CJC-1295 evidence must be interpreted according to the exact formulation studied, particularly when DAC and non-DAC terminology appears.
Frequently asked questions
Peptide Stack Comparison FAQ
What is the GLOW peptide stack?
GLOW is commonly used as a market or research-community name for a three-component combination of GHK-Cu, BPC-157 and TB-500. The name itself does not establish a universal formulation or clinical protocol.
What is the KLOW peptide stack?
KLOW is commonly used for GHK-Cu, BPC-157, TB-500 and KPV. A frequently cited example contains 50 mg GHK-Cu and 10 mg each of BPC-157, TB-500 and KPV, but other formulations exist.
What is the Wolverine peptide stack?
Wolverine is a community nickname commonly associated with BPC-157 plus TB-500. It is not a scientifically standardized formulation.
Is GLOW clinically proven?
Individual components have research histories, but those findings should not be presented as clinical proof for the complete GLOW combination.
Is KLOW clinically proven?
No. Research involving GHK-Cu, BPC-157, TB-500 or KPV individually should not be converted into evidence for the four-component KLOW combination.
Is Wolverine a scientific term?
No. Wolverine is a community/marketing nickname for a BPC-157 and TB-500 pairing.
How do I calculate concentration in a multi-peptide vial?
Divide the mass of each individual component by the final liquid volume. For example, 50 mg of one component in 5 mL is 10 mg/mL, while 10 mg of another component in the same 5 mL is 2 mg/mL.
Can I add all peptide masses together?
You may calculate total peptide mass for descriptive purposes, but you should not use the total mass as the concentration of every individual peptide. Each component has its own mg/mL value.
Does more BAC water change the amount of peptide in the vial?
No. Adding more liquid changes concentration by increasing the final volume. It does not change the labeled mass of each component.
Is CJC-1295 the same with and without DAC?
No. DAC and non-DAC terminology refers to materially different pharmacokinetic characteristics. Human evidence for one form should not automatically be applied to another.
Does evidence for one peptide prove the whole stack works?
No. Combination efficacy and safety require evidence on the actual combination. Individual-component studies are not combination trials.
Primary research references
Scientific References
Teichman SL et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism. PMID 16352683.
FDA Pharmacy Compounding Advisory Committee materials concerning CJC-1295 and related peptide substances, including discussion of human exposure data and formulation distinctions.
Pickart L et al. Research concerning GHK-Cu and tissue remodeling / extracellular matrix biology.
Miller TR et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Archives of Facial Plastic Surgery. PMID 16847171.
Malinda KM et al. Human clinical research involving thymosin beta-4 and venous ulcer healing. PMID 20536470.
Research literature on KPV, including PepT1-mediated uptake and experimental inflammatory models. PMID 18061177.
FDA materials concerning BPC-157, GHK-Cu, CJC-1295, KPV, ipamorelin acetate and thymosin-beta-4 fragment/TB-500.
The references above support component-level scientific context and regulatory interpretation. They should not be read as evidence that GLOW, KLOW or Wolverine is a clinically validated combination.
This page should be reviewed periodically because peptide terminology, commercial formulations, regulatory positions and published evidence can change.
Choosing a selection results in a full page refresh.
